Examination of the mechanism(s) involved in doxorubicin-mediated iron accumulation in ferritin: Studies using metabolic inhibitors, protein synthesis inhibitors, and lysosomotropic agents

被引:64
作者
Kwok, JC [1 ]
Richardson, DR [1 ]
机构
[1] Childrens Canc Inst Australia Med Res, Iron Metab & Chelat Program, Randwick, NSW 2031, Australia
关键词
D O I
10.1124/mol.65.1.181
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Anthracyclines are potent anticancer agents, but their use is limited by cardiotoxicity at high cumulative doses. The mechanisms involved in anthracycline-mediated cardiotoxicity are still poorly understood, but numerous investigations have indicated a role for iron in this process. Our previous studies using neoplastic and myocardial cells showed that anthracyclines inhibit iron mobilization from the iron storage protein, ferritin, resulting in marked accumulation of ferritin-iron. Although the process of ferritin-iron mobilization is little understood, catabolism of ferritin by lysosomes may be a likely mechanism. Because anthracyclines have been shown to accumulate in lysosomes, this latter organelle may be a potential target for these drugs. The present study demonstrated, using native polyacrylamide gel electrophoresis-Fe-59 autoradiography, that ferritin-Fe-59 mobilization is an energy-dependent process that also requires protein synthesis. Depression of lysosomal activity via the enzyme inhibitors E64d [(2S, 3S)-trans-epoxysuccinyl-methylbutane ethyl ester] and leupeptin or the lysosomotropic agents ammonium chloride, chloroquine, and methylamine resulted in a 3- to 5-fold increase in Fe-59-ferritin accumulation compared with control cells. In addition, the proteasome inhibitors N-benzoyloxycarbonyl (Z)-Leu-Leu-leucinal (MG132) and lactacystin also significantly increased Fe-59-ferritin levels compared with control cells. These effects of lysosomotropic agents or inhibitors of lysosomal activity were comparable with that observed with the anthracycline doxorubicin. Collectively, our study indicates a role for lysosomes and proteasomes in ferritin-iron mobilization, and this pathway is dependent on metabolic energy and protein synthesis. Furthermore, the lysosome/proteasome pathway may be a novel anthracycline target, inhibiting iron mobilization from ferritin that is essential for vital iron-requiring processes such as DNA synthesis.
引用
收藏
页码:181 / 195
页数:15
相关论文
共 40 条
[1]   RAPID MOBILIZATION OF FERRITIN IRON BY ASCORBATE IN THE PRESENCE OF OXYGEN [J].
BIENFAIT, HF ;
VANDENBRIEL, ML .
BIOCHIMICA ET BIOPHYSICA ACTA, 1980, 631 (03) :507-510
[2]   RELEASE OF IRON FROM FERRITIN BY XANTHINE-OXIDASE - ROLE OF THE SUPEROXIDE RADICAL [J].
BOLANN, BJ ;
ULVIK, RJ .
BIOCHEMICAL JOURNAL, 1987, 243 (01) :55-59
[3]   Human mitochondrial ferritin expressed in HeLa cells incorporates iron and affects cellular iron metabolism [J].
Corsi, B ;
Cozzi, A ;
Arosio, P ;
Drysdale, J ;
Santambrogio, P ;
Campanella, A ;
Biasiotto, G ;
Albertini, A ;
Levi, S .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (25) :22430-22437
[4]   The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents III: The effect of the ligands on molecular targets involved in proliferation [J].
Darnell, G ;
Richardson, DR .
BLOOD, 1999, 94 (02) :781-792
[5]   Mechanistic studies on the inactivation of the proteasome by lactacystin A central role for clasto-lactacystin beta-lactone [J].
Dick, LR ;
Cruikshank, AA ;
Grenier, L ;
Melandri, FD ;
Nunes, SL ;
Stein, RL .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (13) :7273-7276
[6]   REDUCTIVE MOBILIZATION OF FERRITIN IRON [J].
FUNK, F ;
LENDERS, JP ;
CRICHTON, RR ;
SCHNEIDER, W .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1985, 152 (01) :167-172
[7]  
GIANNI L, 1992, CANC TREATMENT HEART, P9
[8]  
GILJAARD H, 1980, GENETIC METABOLIC DI
[9]   Ferritins: Molecular properties, iron storage function and cellular regulation [J].
Harrison, PM ;
Arosio, P .
BIOCHIMICA ET BIOPHYSICA ACTA-BIOENERGETICS, 1996, 1275 (03) :161-203
[10]  
HERNANDEZYAGO J, 1980, CELL TISSUE RES, V205, P303